Nature, Published online: 15 January 2025; doi:10.1038/d41586-024-04156-w
A phase I clinical trial of GD2-CAR T cells (immune cells engineered to target the molecule GD2) in children and young adults with diffuse midline gliomas — incurable cancers of the central nervous system — shows promising results. Several trial participants exhibited substantial improvements, and one child’s tumour has been undetectable for more than three years.
source
